Tamoxifen alters hepatic cytochrome P450 enzyme expression and circulating growth hormone levels in intact male rats

Pharmaceutical Research

Volumn 21, Issue 9, 2004, Pages 1631-1636

  Ickenstein, Ludger M ^a,b   Holsmer, Susan L ^a   Bandiera, Stelvio M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cytochrome P450; Growth hormone; Hormonal regulation; Tamoxifen; Thyroid hormones

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A1; CYTOCHROME P450 2C11; GROWTH HORMONE; LIOTHYRONINE; OXYGENASE; TAMOXIFEN; TESTOSTERONE 16ALPHA HYDROXYLASE; TESTOSTERONE 2ALPHA HYDROXYLASE; TESTOSTERONE 7ALPHA HYDROXYLASE; THYROXINE; UNCLASSIFIED DRUG; ANTIESTROGEN; THYROID HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CIRCULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; HORMONAL REGULATION; HORMONE BLOOD LEVEL; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; DOSE RESPONSE; ENZYMOLOGY; GENE EXPRESSION; LONG EVANS RAT; METABOLISM;

ANIMALS; BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; GENE EXPRESSION; GROWTH HORMONE; MALE; MICROSOMES, LIVER; RATS; RATS, LONG-EVANS; TAMOXIFEN; THYROID HORMONES;

EID: 21644434573     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000041458.81836.c4     Document Type: Article

References (30)

1. V. C. Jordan. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46:1081-1111 (2003).
2. B. Fisher, J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowl project P-1 study. J. Natl. Cancer Inst. 90:1371-1388 (1998).
3. K. Kostoglou-Athanassiou, Ntalles, J. Gogas, C. Markopoulos, V. Alevizou-Terzaki, P. Athanassiou, E. Georgiou, and C. Proukakis. Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm. Res. 47:116-120 (1995).
4. P. E. Lønning, D. C. Johannessen, E. A. Lien, D. Ekse, T. Fotsis, and H. Adlercreutz. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 52:491-496 (1995).
5. M. N. Pollak, H. T. Huynh, and S. P. LeFebvre. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res. Treat. 22:91-100 (1992).
6. C. C. Mamby, R. R. Love, and K. E. Lee. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J. Clin. Oncol. 13:854-857 (1995).
7. J. Cuzick, D. Allen, M. Baum, J. Barrett, G. Clark, V. Kakkar, E. Melissari, C. Moniz, J. Moore, V. Parsons, K. Pemberton, P. Pitt, W. Richmond, J. Houghton, and D. Riley. Long term effects of tamoxifen. Eur. J. Cancer 29A:15-21 (1992).
8. D. L. Metzger and J. R. Kerrigan. Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: Evidence for a stimulatory role of endogenous estrogens during male adolescence. J. Clin. Endocrinol. Metab. 79:513-518 (1994).
9. G. S. Tannenbaum, W. Gurd, M. Lapinte, and M. Pollak. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130:3395-3401 (1992).
10. V. A. DiPippo, R. Lindsay, and C. A. Powers. Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology 136:1020-1033 (1995).
11. V. A. DiPippo and C. A. Powers. Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. J. Pharmacol. Exp. Ther. 281:142-148 (1997).
12. J. M. Fitts, R. M. Klein, and C. A. Powers. Comparison of tamoxifen effects on the actions of triiodothyronine or growth hormone in the ovariectomized-hypothyroid rat. J. Pharmacol. Exp. Ther. 286:392-402 (1998).
13. A. Bartke, M. Mason, S. Dalterio, and F. Bex. Effects of tamoxifen on plasma concentrations of testosterone and gonadotrophins in the male rat. J. Endocrinol. 79:239-240 (1978).
14. Y. Yamazoe, X. Ling, N. Murayama, D. Gong, K. Nagata, and R. Kato. Modulation of hepatic level of microsomal testosterone 7α-hydroxylase, P-450a (P450IIA), by thyroid hormone and growth hormone in rat liver. J. Biochem. 108:599-603 (1990).
15. D. J. Waxman and T. K. H. Chang. Hormonal regulation of liver cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edition, Plenum Press, New York, 1995, pp. 391-417.
16. M. Kawai, S. M. Bandiera, T. K. H. Chang, F. M. Poulet, P. M. Vancutsem, and G. D. Bellward. Modulation of hepatic CYP2A1, CYP2C11, and CYP3A9 expression in adult rats by neonatal administration of tamoxifen. Drug Metab. Disp. 27:1392-1399 (1999).
17. L. M. Ickenstein and S. M. Bandiera. Persistent suppression of hepatic CYP2A1 expression and serum T3 levels by tamoxifen in intact female rats: Dose-response analysis and comparison with 4-hydroxytamoxifen. ICI 182,780, and 17β-estradiol-3-benzoate. J. Pharmacol. Exp. Ther. 302:584-593 (2002).
18. O. H. Lowry, N. J. Risebrough, A. C. Farr, and R. J. Randall. Protein measurement with the folin reagent. J. Biol. Chem. 193:265-275 (1951).
19. T. Omura and R. Sato. The carbon monoxide binding pigment of liver microsomes II. Solubilization and purification and properties. J. Biol. Chem. 239:2379-2385 (1964).
20. M. D. Anderson, S. M. Bandiera, T. K. H. Chang, and G. D. Bellward. Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. Drug Metab. Disp. 26:1031-1038 (1998).
21. V. C. Jordan. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12:419-424 (1976).
22. P. Greaves, G. Goonetilleke, G. Nunn, J. Topham, and T. Orton. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res. 53:3919-3924 (1993).
23. G. N. Wade and H. W. Heller. Tamoxifen mimics the effect of estradiol on food intake, body weight and body composition in rats. Am. J. Physiol. 264:R1392-R1398 (1993).
24. W. B. Wehrenberg. The role of growth hormone-releasing factor and somatostatin on somatic growth in rats. Endocrinology 118:489-494 (1986).
25. M. D. Lumpkin, S. E. Mulroney, and A. Haramati. Inhibition of pulsatile growth hormone (GH) secretion and somatic growth in immature rats with a synthetic GH-releasing factor antagonist. Endocrinology 124:1154-1159 (1989).
26. I. N. H. White, A. Davies, L. L. Smith, S. Dawson, and F. DeMatteis. Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol. 45:21-30 (1993).
27. O. Putz, C. B. Schwartz, G. A. LeBlanc, R. L. Cooper, and G. S. Prins. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: II. Effects on male puberty and the reproductive tract. Biol. Reprod. 65:1506-1517 (2001).
28. D. J. Waxman, J. J. Morrissey, and G. A. LeBlanc. Female pre-dominant rat hepatic P-450 forms j (IIEI) and 3 (IIAI) are under hormonal regulatory controls distinct from those of the sex-specific P-450 forms. Endocrinology 124:2954-2966 (1989).
29. E. T. Morgan, C. MacGeoch, and J.-Å. Gustafsson. Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16α-hydroxylase cytochrome P-450 apoprotein in the rat. J. Biol. Chem. 260:11895-11898 (1985).
30. S. M. Bandiera and C. Dworschak. Effects of testosterone and estrogen on hepatic levels of cytochromes P450 2C7 and P450 2C11 in the rat. Arch. Biochem. Biophys. 286:286-295 (1992).